Stanford announced on April 10 that it had developed an in-house antibody test that could detect the presence of antibodies for SARS-CoV-2, the virus responsible for COVID-19. Behind the scenes, there was unprecedented collaboration between researchers at Stanford that made it possible to develop an antibody test with such rapid turnaround.
"The pandemic has been the first time that many of us in our lifetimes have seen such a coordination of efforts from entire research communities, not only at Stanford," said Jennifer Cochran who was involved in the effort and is chair of bioengineering.
The Daily interviewed four scientists involved in this effort: Scott Boyd (associate professor of pathology), Jennifer Cochran (chair of bioengineering), Peter Kim (Ph.D. '85, professor of biochemistry), and Ted Jardetzky ('82, professor of structural biology). Each researcher contributed their own expertise and leveraged their resources to make it possible to create a working antibody in two weeks.
Jennifer Cochran helped the team work with industry to scale up production of reagents. Through her efforts, Stanford partnered with the biotechnology companies ATUM and Agilent for large-scale, high-quality manufacturing of the protein reagents needed for antibody testing.
Read the full article on The Stanford Daily